Release Details

Cambridge, Mass. – December 9, 2024 – Biogen Inc. (Nasdaq: BIIB) – today announced the appointment of Tim Power as Vice President, Head of Investor Relations, effective December 9, 2024. Mr. Power will report to Michael McDonnell, Executive Vice President and Chief Financial Officer.

“I am delighted to welcome Tim to Biogen. His exceptional expertise in investor relations and ability to communicate complex business strategies, coupled with his strong background in articulating breakthrough scientific advancements, will be invaluable as we continue to work toward our goal of returning to sustainable growth,” said Mr. McDonnell.

Mr. Power brings over two decades of experience in finance and investor relations, most recently serving as Vice President & Head of Investor Relations at Bristol Myers Squibb (NYSE: BMY), a leading global biopharmaceutical company. While at BMS, Mr. Power successfully managed all aspects of the company's global relationship with the investment community. He played a key role in communicating the company’s strategy, guiding its financial messaging, and engaging with investors during pivotal moments, including the acquisition of Celgene— one of the largest M&A transactions in biopharmaceutical history.

Prior to his leadership role in investor relations, Mr. Power held several strategic and financial positions within BMS, including Director roles in Portfolio & Asset Strategy and Strategic Planning. Earlier in his career, he advanced through strategic consulting and engineering roles at companies such as Strategic Decisions Group and Shell Oil Company.

Mr. Power holds an MBA in Finance from The Wharton School at the University of Pennsylvania, and he earned a PhD in Chemical Engineering from Carnegie Mellon University. He completed his undergraduate studies in Chemical Engineering at University College Dublin, Ireland. 

“I also want to express my personal gratitude to Steve Amato for stepping in as the interim lead for our IR team on top of existing duties. His contributions during this transition have been pivotal in maintaining strong communication with our investors, and we are fortunate to have him on the team,” added Mr. McDonnell.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. 

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor 
This news release contains forward-looking statements, including regarding the potential of Biogen's commercial business and pipeline programs; the anticipated benefits and potential of investments, optimization of our cost structure, Biogen’s future strategic and financial results. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates; actual timing and content of submissions to and decisions made by the regulatory authorities regarding our products or product candidates; uncertainty of success in the development and potential commercialization of the medicine; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.
 

###